Normalised EBITDA was unchanged on YoY basis at Rs 131 crore in Q4 FY23. Normalised EBITDA margin reduced to 26.6% in Q4 FY23 as against 26.9% in Q4 FY22.

Profit before tax in Q4 FY23 stood at Rs 83 crore, down by 0.3% from Rs 84 crore in Q4 FY22.

Dr. Om Manchanda, managing director, said: “Our belief is that the brands that have made comprehensive investments in network creation, infrastructure scale up, and patient services will be the frontrunners of growth. Within healthcare, patients are increasingly aligning themselves with trustworthy brands, and therefore, it is crucial that we improve our on-theground presence and experience. In order to enhance our performance trajectory, we will continue to extend our network into tier 2 and 3 regions of India.”

Bharath Uppiliappan, chief executive officer said: “In the quarter being evaluated, we provided diagnostics services to 6.3 million patients, generating a total revenue of Rs. 491 crore. We actively utilized mixmanagement methods to increase the composition of high-value tests to our portfolio and revenue.”

On full year basis, the company reported 31.2% decline in consolidated net profit to Rs 241.1 crore on 3.4% fall in net sales to Rs 2,016.9 crore in FY23 over FY22.

Meanwhile, the board has recommended final dividend of Rs 6 per equity share for the year ended 31 March 2023, subject to approval of the shareholders.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).